Kristagen vs Thymosin Alpha-1
Comparison of Kristagen (Low evidence) and Thymosin Alpha-1 (Moderate evidence).
Last updated: February 12, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
Kristagen
Dossier overview
Thymosin Alpha-1
Dossier overview
Overview
Kristagen and Thymosin Alpha-1 are both studied in the peptide research space.
Kristagen: A synthetic tripeptide (Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to regulate thymus function and support immune cell differentiation.
Thymosin Alpha-1: A 28-amino acid immunomodulatory peptide approved in over 35 countries including China and Italy for hepatitis B/C, cancer adjuvant therapy, and immunodeficiency.
Evidence Comparison
| Aspect | Kristagen | Thymosin Alpha-1 |
|---|---|---|
| Evidence Level | Low | Moderate |
| Human Studies | 2 | 28 |
| Preclinical Studies | 8 | 14 |
| Total Sources | 12 | 42 |
Key Differences
| Aspect | Kristagen | Thymosin Alpha-1 |
|---|---|---|
| Category | Immune | Immune |
| Evidence Strength | Low | Moderate |
| Total Sources | 12 | 42 |
| Human Studies | 2 | 28 |
Summary
- Kristagen: Low evidence with 12 total sources (2 human)
- Thymosin Alpha-1: Moderate evidence with 42 total sources (28 human)
This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.